IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 30th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 2026...
IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à parti...
AEGON: merger of Corebridge and Equitable, implications for Transamerica. Flow Traders: Equity strong as crypto fades. IBA: Net debt above, FY26 REBIT guidance on the low side, 2H25 REBIT a bit below. Sofina: Final NAV 2% above preliminary results. Zabka: Peer Dino Polska FY25 results
IBA reported solid FY25 results, with revenues up 24% to € 620m (kbcse: € 614m), driven by an accelerated backlog conversion and good order intake. However, gross profit margins still contracted by 150bps to 32.2%, driven by negative mix effects from legacy lower margin PT contracts. Nevertheless, as this was already anticipated, the FY25 REBIT of € 27.4m came in above the guidance of at least € 25m and was in line with our forecast. The 2026 guidance calls for a REBIT of at least € 32m (kbcse: ...
IBA delivers strong FY 2025 results with solid execution in all segments Read the entire full-year 2025 results press release Louvain-la-Neuve, Belgium, 27 March 2026 - IBA (Ion Beam Applications S.A.), today announces its consolidated results of 2025 financial year, with strong execution across the businesses. Robust commercial momentum, notably in Proton Therapy, resulted in a historic order intake and a new all-time high backlog. Delivered in line with guidance, the year marks continued progress in the execution of IBA’s strategic roadmap to the benefit of all its stakeholders. R...
IBA réalise des résultats solides pour l'exercice 2025, avec une exécution maîtrisée dans tous les segments pour lire l'intégralité du communiqué de presse des résultats annuels 2025 Louvain-La-Neuve, Belgique, 27 mars 2026 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour l'exercice 2025, avec une exécution maîtrisée dans tous les segments d'activité. La forte dynamique commerciale, notamment en Proton Therapy, se traduit par une prise de commandes et un carnet de commandes record. Conforme aux objectifs annoncés, l'année a été marquée par la poursu...
Geopolitical risk has resurfaced, but the nearterm impact on European listed real estate remains contained. Rising energydriven inflation and rates are driving greater dispersion and sharpening the focus on balancesheet quality, while MIPIM 2026 highlighted a pragmatic investor approach. In this report, we adjust target prices and refresh our top picks, removing CTP and adding Irish Residential REIT. Geopolitics and energy: duration matters more than headlines
IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy The first wireless ionization chamber array for particle therapy PSQA delivers fast, reliable verification for proton and carbon ion treatments, supporting emerging techniques such as FLASH and ARC radiotherapy. Louvain-la-Neuve, Belgium, 21 March 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global provider of dosimetry and quality assurance (QA) solutions, announces the launch of myQA MatriXX AiR, a high resolution, wireless 2D ionization chamber...
L'IBA lance myQA MatriXX AiR et fait évoluer l'assurance qualité spécifique des patients en thérapie par particules La première gamme de chambres d'ionisation sans fil pour la thérapie par particules, PSQA, fournissant une vérification rapide et fiable des traitements par protons et ions carbone, et adaptée aux techniques émergentes telles que la radiothérapie FLASH et ARC. Louvain-la-Neuve, Belgique, 21 mars 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial de la technologie d'accélérateurs de particules et fournisseur mondial de solutions de dosimétrie et d'assurance qu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.